User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

4749

Interactions with Platform & by Email *

INTERACTIONS

855

Unique # Participated *

PARTICIPANTS

142

Responses Validated *

VALIDATIONS

41

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   RNA Interference: A Historic Perspective.....II-1
RNAi Time Line.....II-1
1$100
   Leading Regional Markets.....II-2
High-throughput Screening: A Promising Application for RNA Interference.....II-2
Growth Drivers.....II-2
1$100
   RNA Interference: A Potential Oligonucleotide Technology.....II-3
A Review of Select Classes of Oligonucleotides Competing with siRNA.....II-3
1$100
   Oligonucleotide Market Sustains Recession.....II-4
Select RNAi-based Therapeutics in the Pipeline.....II-4
2$125
   RNAi: A Leading Research Tool in Gene- Silencing.....II-6
RNAi-based Drugs to Emerge as a New Class of Therapeutics.....II-6
RNAi-based Therapeutics to Drive the Growth of RNAi Market.....II-6
Statistics on Select Diseases.....II-6
Cancer.....II-6
1$100
   Table 1: Global Cancer Incidence by Region: 2009 (includes corresponding Graph/Chart).....II-71$350
   Table 2: Global Cancer Incidence by Country: 2009 (includes corresponding Graph/Chart).....II-81$350
   Table 3: Global Cancer Incidence by Income Group: 2009 (includes corresponding Graph/Chart).....II-9

Table 4: Global Cancer Related Deaths in Male Population by Site: 2007 (includes corresponding Graph/Chart).....II-9
1$350
   Cardiovascular Diseases.....II-10
Table 5: Global Coronary Heart Disease Prevalence by Region (includes corresponding Graph/Chart).....II-10

Table 6: Deaths Due to Major Cardiovascular Diseases in the US: Percentage Share Breakdown by Disease Type (includes corresponding Graph/Chart).....II-10
Huntington’s Disease (HD).....II-10
1$350
   Diabetic Retinopathy.....II-11
Table 7: Diabetic Retinopathy Patient Prevalence in the US by Diabetes Type: 2006-2015 (In Thousand Patients) (includes corresponding Graph/Chart).....II-11

Table 8: Diabetic Retinopathy Patient Prevalence in the US by Age Group: 2006-2012 (includes corresponding Graph/Chart).....II-11
1$350
   Table 9: Diabetic Retinopathy Prevalence in Type-1 Diabetic Patients in the US by Age Group: 2006-2012 (includes corresponding Graph/Chart).....II-12
RNAi in Drug Therapeutics.....II-12
1$350
   RNAi: Select Targeted Clinical Areas.....II-13
Age Related Macular Degeneration: A Key Clinical Area of Focus.....II-13
1$100
   Select Promising RNAi Drugs in Pipeline: A Review.....II-14
ALN-VSP.....II-14
Atu027.....II-14
CALAA-01.....II-14
1$100
   CEQ501.....II-15
RNAi Therapeutics: Challenges in a Nutshell.....II-15
Drug Delivery: A Key Challenge Facing RNAi-based Therapeutics.....II-15
Select Methods of Systemic Drug Delivery under Development.....II-15
1$100
   Select RNAi Drug Delivery Technologies under Development.....II-16
Other Challenges Facing RNAi-based Therapeutics.....II-16
A Snapshot of Select RNAi Delivery Platforms Under Development.....II-16
Lipid Nanoparticle (LNP) siRNA Delivery Technology Platform (Tekmira).....II-16
1$100
   RONDEL (Calando Pharmaceuticals).....II-17
Lipid and Polymer Based Delivery Platforms (Silence Therapeutics).....II-17
AtuPlex/AtuFect Delivery Platform.....II-17
PolyTran™ Delivery Platform.....II-17
1$100
   RNAi Nanoplex Delivery Technology (Intradigm Corporation).....II-18
DiLA2 Platform (Marina Biotech).....II-18
1$100
   History of RNA Interference.....II-19
Co-Suppression and Quelling.....II-19
VIGS (Virus Induced Gene Suppression).....II-19
RNA Interference or Post Transcriptional Silencing.....II-19
The RNAi Pathway.....II-19
1$100
   siRNA and miRNA.....II-20
RISC Complex.....II-20
1$100
   Transfer and Heritance.....II-21
The Difference.....II-21
Other Short RNAs mediating RNA Interference.....II-21
Small Hairpin RNA (shRNA).....II-21
Repeat associated small interfering RNA (rasiRNA).....II-21
1$100
   Comparison of Various Types of RNAs in RNA Interference.....II-221$100
   Significance of RNA Interference.....II-23
Role of RNAi in Gene Silencing.....II-23
RNA Interference Affects Protein Synthesis at the Level of Translation.....II-23
Role of mRNA in Gene Expression.....II-23
1$100
   RNAi: Application Areas.....II-24
RNAi in Drug Discovery and Target Validation.....II-24
RNAi in Functional Genomics.....II-24
Why RNAi over Other Techniques?.....II-24
1$100
   Use of RNAi in the Study of Functional Genomics in Humans.....II-25
Model Organisms and Off-target Effects.....II-25
Select Target Validation Systems.....II-25
RNAiMonitor™ (Clontech Laboratories, Inc).....II-25
1$100
   GenoExplorer™ microRNA System (GenoSensor Corp).....II-26
RNAi Reagents.....II-26
Select RNAi Reagents and Transfection Kits.....II-26
Lipofectamine™ RNAiMAX Transfection Reagent (Life Technologies/Invitrogen).....II-26
1$100
   siGENOME® siRNA Reagents (Dharmacon RNA Technologies).....II-27
ON-TARGETplus™ SMARTpool Reagents (Dharmacon RNA Technologies).....II-27
Vector-based RNAi Reagents (Thermo Scientific).....II-27
siRNA transfection kits (Bio-Rad Lab).....II-27
Fluorescent Reagents (OZ Biosciences).....II-27
ICAFectin™ 442 siRNA Transfection Reagent (Tekmira).....II-27
1$100
   TransIT®-mRNA Transfection Kit (Mirus Bio llc).....II-28
siRNA Synthesis.....II-28
siRNA: A Popular Tool for the Detection and Induction of Gene Silencing.....II-28
Methods of siRNA Synthesis.....II-28
1$100
   Select Synthetic siRNAs.....II-29
Synthetic siRNAs (Eurogentec SA).....II-29
Ambion® In Vivo Pre-designed siRNAs (Life Technologies).....II-29
Silencer® Pre-Designed & Validated siRNAs (Life Technologies).....II-29
1$100
   HuSH-29: pre-designed shRNA (OriGene Technologies, Inc.).....II-30
A Review of other Application Areas of RNAi.....II-30
RNAi in Agriculture and Plant Biotechnology.....II-30
1$100
   miRNA as Biomarkers and Therapeutic Targets – An Insight.....II-31
miRNA: Clinical Areas under Focus.....II-31
1$100
   Asuragen Obtains Notices of Allowance for Several miRNA Patent Applications.....II-32
Genable Technologies Obtains Orphan Designation by EMA.....II-32
Benitec Obtains RNA Interference Patent from EPO.....II-32
Silence Therapeutics Bags New Patent Rights.....II-32
1$100
   Benitec Receives RNAi Related Patent Grant from USPTO.....II-33
Marina Obtains Notices of Allowance for siRNA Patent Applications.....II-33
USPTO Grants a RNAi Related Patent to Benitec.....II-33
Alnylam Receives Patent Rights for Woppmann Patent Series.....II-33
1$100
   Kylin Bags Patent Rights for pRNAi Technology.....II-34
Allele Biotechnology Obtains Patent Approval for DNA-Encoded RNAi.....II-34
Silence Therapeutics Obtains Notices of Allowance for RNAi Patent Applications.....II-34
1$100
   RXi Obtains Notices of Allowance for siRNA Patent Applications.....II-35
Intradigm Obtains Patent for siRNA Sequence.....II-35
Intradigm Receives Key RNAi Patent Allowance.....II-35
2$125
   Exiqon Launches miRCURY LNA™ miRNA Family Inhibitors.....II-37
Cellecta Introduces New Open Source Genome-Wide RNAi Screening Platform.....II-37
Tekmira, Alnylam, and UBC Co-Develop New Lipid Component.....II-37
1$100
   ID Tech Introduces Improved miRCat™ Small RNA Cloning System.....II-38
Integrated DNA Technologies Launches Transductin™.....II-38
1$100
   Abnova Unveils New Gene Silencing Tool.....II-39
Polyplus-transfection Introduces jetPRIME™ Transfection Reagent.....II-39
Sigma-Aldrich Launches Gene-Specific MISSION esiRNA.....II-39
CombiMatrix to Introduce miRNA Cancer-Screening Test in the US.....II-39
1$100
   GeneCopoeia Unveils microRNA Tools and Reagents for Functional Analysis.....II-40
Invitrogen Introduces Invivofectamine™ Delivery Reagent.....II-40
1$100
   RXi Pharmaceuticals Corp. is Now Galena Biopharma.....II-41
Cenix to Establish New Subsidiary.....II-41
Arrowhead Acquires Stake in US Subsidiary, Calando.....II-41
1$100
   RXi and Generex Obtain Positive Research Data for Exploring RNAi Technology.....II-42
Rosetta Obtains Permit for miRNA-based Diagnostics in NY.....II-42
Alnylam Pharmaceuticals Introduces Alnylam 5x15 Product Strategy.....II-42
Cenix BioScience Receives R&D Grant from Saxony.....II-42
1$100
   Kyowa and Dicerna Expand Research Collaboration.....II-43
MDRNA Acquires BNA Intellectual Property from Valeant.....II-43
1$100
   Sirnaomics Partners with a Chinese Company for RNAi Therapeutics Development.....II-44
Kylin Obtains IRS Grant for Advancing Research on pRNAi Nanoparticle.....II-44
Tekmira Obtains New License for Alnylam’s InterfeRx™.....II-44
1$100
   RXi to Collaborate with EyeGate.....II-45
Sigma Life Partners with SwitchGear Genomics for miRNA Validation System.....II-45
Marina Biotech Acquires Novosom’s SMARTICLES® Intellectual Property Estate.....II-45
1$100
   Quark to Collaborate with Nitto Denko for Co-Developing siRNA-based Anti-fibrotic
  Drug.....II-46
AstraZeneca and Silence Therapeutics Extend R&D Alliance.....II-46
Silence Therapeutics and AstraZeneca Extend siRNA Delivery Partnership.....II-46
1$100
   MDRNA to Take Over Cequent.....II-47
Traversa and sanofi-aventis Ink Research Agreement.....II-47
Pfizer to Develop HCV Compounds of Tacere Therapeutics.....II-47
Intradigm and Silence Therapeutics Merge.....II-47
1$100
   Sirna Therapeutics and Allergan form Joint Drug Development Alliance.....II-48
Benitec Collaborates with CCIA.....II-48
RXi Pharmaceuticals Obtains Advirna’s RNAi Technology.....II-48
1$100
   RXi Obtains Exclusive Licensing Rights to Advirna’s Delivery Technologies.....II-49
Dicerna Collaborates with Archemix.....II-49
Alnylam Collaborates with GSK to Donate Several RNAi Technology Patents.....II-49
AstraZeneca and Cenix Extend Research Agreement on RNA Interference.....II-49
1$100
   Allergan Stops Development of AGN-745 Treatment.....II-50
Tekmira Inks Agreement with Roche.....II-50
MDRNA Inks Licensing Agreement with Novartis.....II-50
MDRNA Inks Agreement with Roche for Developing RNAi Therapeutics.....II-50
1$100
   Mirna Therapeutics to Investigate Therapeutic Potential of miRNA.....II-51
Cenix and Boehringer Ingelheim Ink Research Agreement.....II-51
Mirna and M. D. Anderson to Explore miRNA Therapeutics in Prostate Cancer.....II-51
Cubist Partners with Alnylam Pharmaceuticals.....II-51
1$100
   Liquidia to License Certain Rights of PRINT technology to Abbott.....II-521$100
   Invitrogen Merges with Applied Biosystems.....II-53
MDRNA Obtains Rights to RiboTask’s UNA Technology.....II-53
Roche Takes Over Mirus.....II-53
Thermo Fischer Snaps Up Open Biosystems.....II-53
1$100
   Protiva and Tekmira Complete the Merger of Business Operations.....II-54
Takeda and Alnylam Enter into Strategic Alliance.....II-54
1$100
   SR Pharma Plc. is Now Silence Therapeutics Plc......II-551$100
   Alnylam Pharmaceuticals, Inc. (USA).....II-561$100
   Benitec Limited (Australia).....II-571$100
   Bioneer Corp. (Korea).....II-58
Calando Pharmaceuticals, Inc. (USA).....II-58
1$100
   Cenix BioScience GmbH (Germany).....II-59
Devgen NV (Belgium).....II-59
Dharmacon, Inc. (USA).....II-59
2$125
   Dicerna Pharmaceuticals, Inc. (USA).....II-61
Exiqon A/S (Denmark).....II-61
Genesis Research & Development Corporation Limited (New Zealand).....II-61
1$100
   Halo-Bio RNAi Therapeutics, Inc. (USA).....II-62
Marina Biotech, Inc. (USA).....II-62
1$100
   OPKO Health, Inc. (USA).....II-63
Polyplus-transfection SA (France).....II-63
1$100
   Quark Pharmaceuticals, Inc. (USA).....II-64
Galena Biopharma (USA).....II-64
1$100
   Sigma-Aldrich Co. (USA).....II-65
Silence Therapeutics (UK).....II-65
1$100
   Tekmira Pharmaceuticals Corp. (Canada).....II-662$125
   Table 10: World Recent Past, Current & Future Analysis for RNA Interference by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-681$350
   Table 11: World Historic Review for RNA Interference by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-691$350
   Table 12: World 15-Year Perspective for RNA Interference by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....II-701$350
   Table 13: World Recent Past, Current & Future Analysis for RNA Interference in Drug Discovery and Target Validation Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-711$350
   Table 14: World Historic Review for RNA Interference in Drug Discovery and Target Validation Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-721$350
   Table 15: World 15-Year Perspective for RNA Interference in Drug Discovery and Target Validation Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....II-731$350
   Table 16: World Recent Past, Current & Future Analysis for RNA Interference Reagents by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-741$350
   Table 17: World Historic Review for RNA Interference Reagents by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-751$350
   Table 18: World 15-Year Perspective for RNA Interference Reagents by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....II-761$350
   Table 19: World Recent Past, Current & Future Analysis for siRNA Synthesis by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-771$350
   Table 20: World Historic Review for siRNA Synthesis by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-781$350
   Table 21: World 15-Year Perspective for siRNA Synthesis by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....II-791$350
   A. Market Analysis.....III-1
Outlook.....III-1
Technological Innovations.....III-1
3$125
   Strategic Corporate Developments.....III-48$225
   Focus on Select Major Players.....III-126$175
   B. Market Analytics.....III-18
Table 22: The US Recent Past, Current & Future Analysis for RNA Interference by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-18
1$200
   Table 23: The US Historic Review for RNA Interference by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-191$200
   Table 24: The US 15-Year Perspective for RNA Interference by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-201$200
   A. Market Analysis.....III-21
Strategic Corporate Development.....III-21
Focus on Select Major Player.....III-21
1$75
   B. Market Analytics.....III-22
Table 25: Canadian Recent Past, Current & Future Analysis for RNA Interference by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-22
1$200
   Table 26: Canadian Historic Review for RNA Interference by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-231$200
   Table 27: Canadian 15-Year Perspective for RNA Interference by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-241$200
   A. Market Analysis.....III-25
Strategic Corporate Developments.....III-25
2$100
   B. Market Analytics.....III-27
Table 28: Japanese Recent Past, Current & Future Analysis for RNA Interference by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-27
1$200
   Table 29: Japanese Historic Review for RNA Interference by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-281$200
   Table 30: Japanese 15-Year Perspective for RNA Interference by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-291$200
   Market Analytics.....III-30
Table 31: European Recent Past, Current & Future Analysis for RNA Interference by Geographic Region - France, Germany, Italy, UK, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-30
1$200
   Table 32: European Historic Review for RNA Interference by Geographic Region - France, Germany, Italy, UK, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-311$200
   Table 33: European 15-Year Perspective for RNA Interference by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, and Rest of Europe Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-321$200
   Table 34: European Recent Past, Current & Future Analysis for RNA Interference by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-331$200
   Table 35: European Historic Review for RNA Interference by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-341$200
   Table 36: European 15-Year Perspective for RNA Interference by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-351$200
   A. Market Analysis.....III-36
Technological Innovation.....III-36
Strategic Corporate Development.....III-36
Focus on Select Major Player.....III-36
1$75
   B. Market Analytics.....III-37
Table 37: French Recent Past, Current & Future Analysis for RNA Interference by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-37
1$200
   Table 38: French Historic Review for RNA Interference by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-381$200
   Table 39: French 15-Year Perspective for RNA Interference by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-391$200
   A. Market Analysis.....III-40
Strategic Corporate Developments.....III-40
1$75
   B. Market Analytics.....III-41
Table 40: German Recent Past, Current & Future Analysis for RNA Interference by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-41
1$200
   Table 41: German Historic Review for RNA Interference by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-421$200
   Table 42: German 15-Year Perspective for RNA Interference by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-431$200
   Market Analytics.....III-44
Table 43: Italian Recent Past, Current & Future Analysis for RNA Interference by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-44
1$200
   Table 44: Italian Historic Review for RNA Interference by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-451$200
   Table 45: Italian 15-Year Perspective for RNA Interference by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-461$200
   A. Market Analysis.....III-47
Technological Innovations.....III-47
1$75
   Focus on Select Major Player.....III-481$75
   B. Market Analytics.....III-49
Table 46: The UK Recent Past, Current & Future Analysis for RNA Interference by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-49
1$200
   Table 47: The UK Historic Review for RNA Interference by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-501$200
   Table 48: The UK 15-Year Perspective for RNA Interference by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-511$200
   A. Market Analysis.....III-52
Strategic Corporate Developments.....III-52
1$75
   Focus on Select Major Players.....III-532$100
   B. Market Analytics.....III-55
Table 49: Rest of European Recent Past, Current & Future Analysis for RNA Interference by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-55
1$200
   Table 50: Rest of European Historic Review for RNA Interference by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-561$200
   Table 51: Rest of European 15-Year Perspective for RNA Interference by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-571$200
   A. Market Analysis.....III-58
Strategic Corporate Developments.....III-58
1$75
   Focus on Select Major Players.....III-593$125
   B. Market Analytics.....III-62
Table 52: Asia-Pacific Recent Past, Current & Future Analysis for RNA Interference by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-62
1$200
   Table 53: Asia-Pacific Historic Review for RNA Interference by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-631$200
   Table 54: Asia-Pacific 15-Year Perspective for RNA Interference by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-641$200
   Market Analytics.....III-65
Table 55: Rest of World Recent Past, Current & Future Analysis for RNA Interference by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-65
1$200
   Table 56: Rest of World Historic Review for RNA Interference by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-661$200
   Table 57: Rest of World 15-Year Perspective for RNA Interference by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-671$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com